3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
14
Breast
8
Gastrointestinal
5
Head & Neck
3
Gynecologic
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Classical hematology
1
Conditions
Brain Neoplasms
1905
Glioblastoma
1797
Glioma
1130
Central Nervous System Neoplasms
599
Astrocytoma
594
Neuroblastoma
552
Gliosarcoma
465
Oligodendroglioma
364
Neoplasms
312
Breast Neoplasms
273
Medulloblastoma
272
Carcinoma, Non-Small-Cell Lung
227
Recurrence
199
Sarcoma
184
Neoplasm Metastasis
183
Melanoma
182
Meningioma
177
Ependymoma
176
Lung Neoplasms
157
Lymphoma
134
Osteosarcoma
127
Meningeal Carcinomatosis
126
Neurofibromatosis 1
114
Wilms Tumor
111
Ovarian Neoplasms
110
Diffuse Intrinsic Pontine Glioma
105
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Rhabdomyosarcoma
101
Lymphoma, Non-Hodgkin
96
Burkitt Lymphoma
89
Interventions
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Second Primary
×
CNS
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts
NCT00629187
2012-04-27
CN-306
Tufts Medical Center
Phase 1
Terminated
2 enrolled